Cargando…
Alzheimer’s Disease—Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran
Alzheimer’s disease (AD) is caused by neurodegenerative, but also vascular and hemostatic changes in the brain. The oral thrombin inhibitor dabigatran, which has been used for over a decade in preventing thromboembolism and has a well-known pharmacokinetic, safety and antidote profile, can be an opt...
Autor principal: | Grossmann, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125318/ https://www.ncbi.nlm.nih.gov/pubmed/33946588 http://dx.doi.org/10.3390/ijms22094805 |
Ejemplares similares
-
Boehringer launches first direct thrombin inhibitor: dabigatran (Pradaxa®)
Publicado: (2010) -
Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations
por: Xu, Xiaoping, et al.
Publicado: (2019) -
Dabigatran reduces thrombin-induced neuroinflammation and AD markers in vitro: Therapeutic relevance for Alzheimer's disease
por: Bihaqi, Syed Waseem, et al.
Publicado: (2021) -
Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer’s Disease
por: Grossmann, Klaus
Publicado: (2022) -
Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function
por: Yeh, Calvin H., et al.
Publicado: (2016)